1. MP55-20 ESTABLISHMENT OF LUCAP CELL LINES BY “ORGANOID” IN VITRO CULTURE TECHNOLOGY

    The Journal of Urology 193(4):e680 (2015)

  2. MP46-06 ABLATION OF INTRATUMORAL ANDROGENESIS IN PROSTATE TUMOR CELL XENOGRAFTS BY A HEDGEHOG SIGNALING INHIBITOR

    The Journal of Urology 193(4):e545 (2015)

  3. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

    International Journal of Oncology 46(4):1560 (2015) PMID 25634071

    Resistance of prostate cancer to castration is currently an unavoidable problem. The major mechanisms underlying such resistance are androgen receptor (AR) overexpression, androgen-independent activation of AR, and AR mutation. To address this problem, we developed an AR pure antagonist, CH51372...
  4. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

    International Journal of Oncology 46(4):1560 (2015) PMID 25634071

    Resistance of prostate cancer to castration is currently an unavoidable problem. The major mechanisms underlying such resistance are androgen receptor (AR) overexpression, androgen-independent activation of AR, and AR mutation. To address this problem, we developed an AR pure antagonist, CH51372...
  5. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

    Prostate 75(3):303 (2015) PMID 25327986

    It is timely and important to develop new treatment modalities for advanced prostate cancer, because even the newly FDA approved treatments, despite providing significant survival benefits, do not constitute cure of this disease. Antibody drug conjugates (ADCs) represent a promising approach to ...
  6. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

    Prostate 75(3):303 (2015) PMID 25327986

    It is timely and important to develop new treatment modalities for advanced prostate cancer, because even the newly FDA approved treatments, despite providing significant survival benefits, do not constitute cure of this disease. Antibody drug conjugates (ADCs) represent a promising approach to ...
  7. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

    Prostate 75(3):303 (2015) PMID 25327986

    It is timely and important to develop new treatment modalities for advanced prostate cancer, because even the newly FDA approved treatments, despite providing significant survival benefits, do not constitute cure of this disease. Antibody drug conjugates (ADCs) represent a promising approach to ...
  8. Cellular Adhesion Promotes Prostate Cancer Cells Escape from Dormancy.

    PLoS ONE 10(6):e0130565 (2015) PMID 26090669 PMCID PMC4475050

    Dissemination of prostate cancer (PCa) cells to the bone marrow is an early event in the disease process. In some patients, disseminated tumor cells (DTC) proliferate to form active metastases after a prolonged period of undetectable disease known as tumor dormancy. Identifying mechanisms of PCa...
  9. The Androgen-Regulated Protease TMPRSS2 Activates a Proteolytic Cascade Involving Components of the Tumor Microenvironment and Promotes Prostate Cancer Metastasis.

    Cancer Discovery 4(11):1310 (2014) PMID 25122198

    TMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastases. Through the generation of mouse models with a targeted delet...
  10. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

    Cancer Discovery 4(11):1310 (2014) PMID 25122198

    TMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastases. Through the generation of mouse models with a targeted delet...
  11. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis.

    Cancer Discovery 4(11):1310 (2014) PMID 25122198 PMCID PMC4409786

    TMPRSS2 is an androgen-regulated cell-surface serine protease expressed predominantly in prostate epithelium. TMPRSS2 is expressed highly in localized high-grade prostate cancers and in the majority of human prostate cancer metastases. Through the generation of mouse models with a targeted delet...
  12. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.

    Cancer Research 74(16):4306 (2014) PMID 24970477

    The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone...
  13. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.

    Cancer Research 74(16):4306 (2014) PMID 24970477

    The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone...
  14. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.

    Cancer Research 74(16):4306 (2014) PMID 24970477

    The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone...
  15. AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis.

    Cancer Research 74(16):4306 (2014) PMID 24970477 PMCID PMC4429795

    The recurrence of prostate cancer metastases to bone after androgen deprivation therapy is a major clinical challenge. We identified FN14 (TNFRSF12A), a TNF receptor family member, as a factor that promotes prostate cancer bone metastasis. In experimental models, depletion of FN14 inhibited bone...
  16. Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

    Cancer Research 74(8):2270 (2014) PMID 24556717 PMCID PMC4012562

    Prostate cancer growth depends on androgen receptor signaling. Androgen ablation therapy induces expression of constitutively active androgen receptor splice variants that drive disease progression. Taxanes are a standard of care therapy in castration-resistant prostate cancer (CRPC); however, m...
  17. Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

    Cancer Research 74(8):2270 (2014) PMID 24556717 PMCID PMC4012562

    Prostate cancer growth depends on androgen receptor signaling. Androgen ablation therapy induces expression of constitutively active androgen receptor splice variants that drive disease progression. Taxanes are a standard of care therapy in castration-resistant prostate cancer (CRPC); however, m...
  18. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

    Clinical & Experimental Metastasis 31(2):247 (2014) PMID 24242705 PMCID PMC3946934

    Approximately 90 % of patients who die of prostate cancer (PCa) have bone metastases, often promoting osteoblastic lesions. We observed that 88 % of castration-resistant PCa (CRPC) bone metastases express prostatic acid phosphatase (PAP), a soluble secreted protein expressed by prostate epitheli...
  19. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

    Clinical & Experimental Metastasis 31(2):247 (2014) PMID 24242705 PMCID PMC3946934

    Approximately 90 % of patients who die of prostate cancer (PCa) have bone metastases, often promoting osteoblastic lesions. We observed that 88 % of castration-resistant PCa (CRPC) bone metastases express prostatic acid phosphatase (PAP), a soluble secreted protein expressed by prostate epitheli...
  20. Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

    Clinical & Experimental Metastasis 31(2):247 (2014) PMID 24242705 PMCID PMC3946934

    Approximately 90 % of patients who die of prostate cancer (PCa) have bone metastases, often promoting osteoblastic lesions. We observed that 88 % of castration-resistant PCa (CRPC) bone metastases express prostatic acid phosphatase (PAP), a soluble secreted protein expressed by prostate epitheli...